Ottimo Pharma Secures $140 Million Funding for Revolutionary Cancer Therapies

Ottimo Pharma, a pioneering biotechnology company established in 2020 and co-founded by Medicxi and Jonny Finlay, has successfully raised $140 million in a recent funding round. This substantial injection of capital will significantly accelerate the company’s mission to develop groundbreaking cancer therapies specifically targeting solid tumors. Ottimo Pharma has garnered attention for its innovative lead program, Jankistomig, a revolutionary PD1-VEGFR2 bi-functional antibody that uniquely combines immune checkpoint inhibition with angiogenesis targeting in a single IgG therapy. This dual-pathway strategy is designed not only to enhance treatment efficacy but also to improve overall patient outcomes and alleviate the healthcare system's burden caused by cancer. Under the guidance of a world-class leadership team, including Chair and CEO David Epstein, CMO Mehdi Shahidi, and Vice-Chair James Sabry, Ottimo Pharma is poised for significant advancements in oncological care. The company is currently on track to file an Investigational New Drug (IND) application in late 2025, marking a critical milestone in the journey toward bringing Jankistomig to clinical trials. The recent funding will facilitate further research and development initiatives, paving the way for Ottimo Pharma to emerge as a leader in oncology solutions and reaffirm its commitment to transforming cancer treatment for patients worldwide.